BeOne Medicines Ltd. Q2 FY2025 earnings call

• John Oyler highlighted a spectacular second quarter with $1.3 billion revenue, 42% Y/Y growth, $220 million FCF. BRUKINSA is the #1 BTK inhibitor in the U.S. and was the focus of an R&D Day with key takeaways on internal capabilities, hematology franchise, and solid tumor pipeline.
• Aaron Rosenberg discussed product revenue growth, BRUKINSA's global success, margin expansion (GAAP gross margin mid- to high 80% range), updated full-year 2025 guidance (revenue $5B-$5.3B), and financials including net income of $94M and non-GAAP net income of $253M.
• Lai Wang talked about R&D progress, including filing NDAs for sonro, progress in CLL franchise with combination therapies, solid tumor pipeline updates, and milestones like global filing of sonro and pivotal data for BTK CDAC.

Product revenue reached $1.3 billion in the second quarter, representing 41% year-over-year growth. BRUKINSA's global revenues were $950 million, growing 49% year-over-year. BRUKINSA's U.S. revenue was $685 million, with a 43% year-over-year growth. China revenue totaled $429 million, a 23% increase. Europe contributed $152 million, with 87% year-over-year growth. Rest of world markets grew 168%. TEVIMBRA reported a 22% increase, and in-licensed products grew 27% year-over-year. BRUKINSA is the #1 BTK inhibitor in the U.S. market, with global revenues driven by strong performance across all geographies.

• Total revenue expectations for 2025 range between $5 billion and $5.3 billion.
• GAAP gross margin mid- to high 80% range reflecting favorable mix dynamics and cost efficiencies.
• Operating expenses projected between $4.1 billion and $4.4 billion.
• Expect to generate positive free cash flow for the year.

• Competition aggressively discounting despite BRUKINSA's market position.
• Uncertainty around U.S. tariffs and their potential impact on gross margin, with ongoing monitoring and agility in response required.

Q: Congrats on a strong quarter. On BRUKINSA, any change in net price expectation? Reaction to BRUIN-CLL-314 data? CDK4 Phase III trial start?

A: Matt Shaulis stated stable pricing through remainder of year; Lai Wang noted BRUIN314 not formally testing superiority, ALPINE study remains key; Mark Lanasa said delay in CDK4 Phase III trial to mature data, intent to start frontline study in 2026 and share data at San Antonio Breast Cancer Symposium.

Q: On CELESTIAL-TNCLL trial, market playout, pricing, time-based therapy?

A: Matt Shaulis said optimistic about zani plus sonro, stable BTK mono expected, bigger opportunities for fixed duration later; Lai Wang discussed resistance mechanisms and need for BTK inhibitors to demonstrate superiority over BRUKINSA.

Q: On financials, gross margin improvement, U.S. tariff impact?

A: Aaron Rosenberg said gross margin improvement from production efficiencies, TEVIMBRA, price, and mix; tariff impact mitigated by global supply chain, monitoring Section 232 investigation.

Q: On filing, BRUKINSA net pricing benefit, future net pricing?

A: Aaron Rosenberg said mid-single-digit pricing benefit in U.S. from early year price increases and Part D reform, stable net pricing expected going forward.

Q: On revenue guidance, R&D milestones, BTK degrader resistance vs pirto?

A: Aaron Rosenberg said revenue guidance reflects execution, Lai Wang discussed BTK degrader resistance to certain mutations, and R&D milestones like sonro global filing, degrader pivotal Phase II readout.

Q: On BRUKINSA access, global revenue mix, tablet formulation impact?

A: Matt Shaulis said confident in BRUKINSA access with HCP and patient preference; Xiaobin Wu noted global revenue growth in all regions, expanding footprint; Matt Shaulis said tablet formulation is patient-focused, will solidify market leadership and replace capsule eventually.

Q: On covalent BTK inhibitor market, first-line MCL for BRUKINSA, BTK degrader in autoimmune?

A: Matt Shaulis said market growth driven by longer DOT, CLL as main driver; Lai Wang discussed BTK degrader potential in autoimmune with long half-life, penetration, and degrader mechanism.